ArticleCancer immunology, immunotherapy : CII2026
Predictive value of natural killer (NK) cells in bone marrow for relapse in diffuse large B cell lymphoma: integrating antibody-dependent cell-mediated cytotoxicity (ADCC)-based immunotherapy.
Article in Cancer immunology, immunotherapy : CII, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDiffuse large B cell lymphoma (DLBCL) is characterized by high relapse rates and immunobiological complexity. The therapeutic efficacy of CD20-targeting monoclonal antibodies depends largely on antibody-dependent cellular cytotoxicity (ADCC), mediated by natural killer (NK) cells.
methodsWe evaluated the percentage of bone marrow NK cells in 47 newly diagnosed DLBCL patients by flow cytometry prior to first-line chemoimmunotherapy. ADCC potential was assessed using immunological parameters.
resultsPatients with ≥ 14% bone marrow NK cells had significantly better event-free survival (EFS), with median EFS nearly doubled compared with those below this threshold (HR = 0.24, p < 0.05). Logistic regression predicted a 77% probability of remaining relapse-free at NK percentages > 14%. In multivariable Cox regression, bone marrow NK percentage remained independently predictive of EFS after adjustment for International Prognostic Index (IPI), age, and treatment regimen. Although overall survival did not differ significantly, higher NK levels were associated with improved clinical response.
conclusionPatients with higher NK cell percentages may better tolerate chemotherapy-induced depletion, thereby preserving or restoring their effector pool more efficiently. Elevated bone marrow NK cell percentages predict favorable outcomes in DLBCL and support their potential role as translational biomarkers. Incorporating NK cell monitoring into clinical protocols could improve risk stratification and guide immunotherapeutic strategies for personalized patient management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.